Tag: Branched-chain fatty acid anticonvulsant / mood stabilizer

  • Sodium Valproate

    Branched-chain fatty acid anticonvulsant / mood stabilizer

    A simple branched-chain fatty acid with broad anticonvulsant activity and mood-stabilizing efficacy in bipolar disorder.

    Abstract

    Sodium valproate (sodium 2-propylpentanoate; CAS 1069-66-5; molecular formula C8H15NaO2; molecular weight 166.20) is a branched-chain fatty acid anticonvulsant first characterized as bioactive in 1962 (incidentally, while serving as a solvent in pharmacological screening at Lyon). Approved by the FDA in 1978 (Depakote, the divalproex sodium delayed-release form). Mechanism is multifactorial: GABA transaminase inhibition increases brain GABA; sodium channel blockade reduces neuronal hyperexcitability; T-type calcium channel inhibition supports anti-absence activity; histone deacetylase (HDAC) inhibition modifies gene expression with neuroprotective and possibly disease-modifying implications in bipolar disorder. Plasma half-life is 9 to 16 hours; metabolism is via beta-oxidation, omega-oxidation, and glucuronidation. Approved indications include all major seizure types (partial, generalized tonic-clonic, absence, myoclonic), bipolar I disorder mania, and migraine prophylaxis. The principal limitation is teratogenicity (neural tube defects, cognitive deficits in offspring) requiring strict avoidance in pregnancy and women of childbearing age. Hepatotoxicity, pancreatitis, and hyperammonemia are recognized adverse events. Used as the canonical broad-spectrum anticonvulsant and HDAC inhibitor reference.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.